PMID- 2018379
OWN - NLM
STAT- MEDLINE
DCOM- 19910523
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 11
IP  - 1
DP  - 1991 Jan-Feb
TI  - The effect of lonidamine alone and in combination with cisplatin on in vitro 
      growth and viability of lung squamous cell carcinoma cell lines.
PG  - 41-7
AB  - Two non small cell lung cancer (NSCLC) cell lines were tested in vitro to 
      evaluate the effect of lonidamine, cisplatin and combinations of these two agents 
      using different doses and schedules. Lonidamine alone at concentrations greater 
      than 50 micrograms/ml caused inhibition of cell growth in both monolayer and 
      spheroid cell cultures. Cisplatin at concentrations of 10-20 microM caused a 
      concentration dependent toxicity and inhibited growth in monolayer and spheroid 
      cell cultures. Combination treatment of lonidamine and cisplatin caused 
      concentration dependent effects. For 25 micrograms/ml lonidamine, there was no 
      additive and in some cases an antagonistic effect when used with cisplatin. For 
      higher lonidamine concentrations (75 and 100 micrograms ml), an additive effect 
      with cisplatin (10-15 microM) was observed. This effect saturated for cisplatin 
      concentrations of 20 microM. These data show some potential for lonidamine and 
      cisplatin combination therapy but treatment doses and schedules will have to be 
      identified so that the additive effect can be achieved at concentrations 
      clinically attainable.
FAU - Raaphorst, G P
AU  - Raaphorst GP
AD  - Ottawa Regional Cancer Centre, Ontario, Canada.
FAU - Ko, D
AU  - Ko D
FAU - Feeley, M M
AU  - Feeley MM
FAU - Danjoux, C E
AU  - Danjoux CE
FAU - Maroun, J
AU  - Maroun J
FAU - Evans, W K
AU  - Evans WK
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indazoles)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U78804BIDR (lonidamine)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Carcinoma, Squamous Cell
MH  - Cell Division/drug effects
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Cisplatin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Indazoles/*pharmacology
MH  - Kinetics
MH  - Lung Neoplasms
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1991 Jan-Feb;11(1):41-7.